May 7, 2019
Takeda Pharmaceutical’s inflammatory bowel disease medicine Entyvio (vedolizumab) is expected to receive the green light in May for an additional indication of Crohn’s disease (CD) after the health ministry reported its planned approval to a key panel on April 26...read more